Aripiprazole is believed to cause less body weight gain than other atypical antipsychotics. It could decrease the body weight and improve metabolic parameters of overweight patients treated with olanzapine.1 The relatively pure affinity for dopamine receptors might produce less weight gain.2 Its metabolic and cardiovascular complications were fewer than those of other atypical antipsychotics, such as olanzapine.3 Aripiprazole is also recommended as a therapeutic substitution for schizophrenic patients with cardiovascular complications related to atypical antipsychotics. However, Fava et al. found that adjunctive aripiprazole probably contributed to weight gain in patients with major depressive disorder.4 The 5-HT2C receptor is important for appetite and weight control. The authors suggested that potent serotonin 5-HT2C binding of aripiprazole2 might be related to weight gain and metabolic changes in this patient. The dietitian used the Harris-Benedict Equation5 to calculate the basic energy expenditure and subsequent caloric requirement for a body weight-control plan. The patient planned to lose weight by subtracting 500 kcal from her daily requirement, which should decrease weight 1–2 pounds per week. The dietary plan was according to the American Dietary Association guidelines for food, with protein around 15%–20%, fat: 25%–30%, and carbohydrates: 50%–60%. Her exercise habits should also reduce 2 kg of weight by increasing caloric consumption. However, her body weight gain persisted, with a dramatic increase after quitting diet counseling. From the above findings, we suggest that aripiprazole fails to produce weight loss, but nutritional counseling might be advantageous. The promotion of nutritional counseling for schizophrenic patients could be considered, even with those antipsychotics with lower risk for metabolic syndrome, such as aripiprazole.